These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 18855880)

  • 1. Modelling the monetary value of a QALY: a new approach based on UK data.
    Mason H; Jones-Lee M; Donaldson C
    Health Econ; 2009 Aug; 18(8):933-50. PubMed ID: 18855880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimating a WTP-based value of a QALY: the 'chained' approach.
    Robinson A; Gyrd-Hansen D; Bacon P; Baker R; Pennington M; Donaldson C;
    Soc Sci Med; 2013 Sep; 92():92-104. PubMed ID: 23849283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GET MORE, PAY MORE? An elaborate test of construct validity of willingness to pay per QALY estimates obtained through contingent valuation.
    Bobinac A; van Exel NJ; Rutten FF; Brouwer WB
    J Health Econ; 2012 Jan; 31(1):158-68. PubMed ID: 22018622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring a new method for deriving the monetary value of a QALY.
    Tilling C; Krol M; Attema AE; Tsuchiya A; Brazier J; van Exel J; Brouwer W
    Eur J Health Econ; 2016 Sep; 17(7):801-9. PubMed ID: 26289341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Valuing lives and life years: anomalies, implications, and an alternative.
    Dolan P; Metcalfe R; Munro V; Christensen MC
    Health Econ Policy Law; 2008 Jul; 3(Pt 3):277-300. PubMed ID: 18634620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness?
    Shiroiwa T; Sung YK; Fukuda T; Lang HC; Bae SC; Tsutani K
    Health Econ; 2010 Apr; 19(4):422-37. PubMed ID: 19382128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is it really possible to build a bridge between cost-benefit analysis and cost-effectiveness analysis?
    Dolan P; Edlin R
    J Health Econ; 2002 Sep; 21(5):827-43. PubMed ID: 12349884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eliciting Societal Preferences for Weighting QALYs for Burden of Illness and End of Life.
    Rowen D; Brazier J; Mukuria C; Keetharuth A; Risa Hole A; Tsuchiya A; Whyte S; Shackley P
    Med Decis Making; 2016 Feb; 36(2):210-22. PubMed ID: 26670663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving Cross-Sector Comparisons: Going Beyond the Health-Related QALY.
    Brazier J; Tsuchiya A
    Appl Health Econ Health Policy; 2015 Dec; 13(6):557-65. PubMed ID: 26324402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Searchers vs surveyors in estimating the monetary value of a QALY: resolving a nasty dilemma for NICE.
    Baker R; Chilton S; Donaldson C; Jones-Lee M; Lancsar E; Mason H; Metcalf H; Pennington M; Wildman J
    Health Econ Policy Law; 2011 Oct; 6(4):435-47. PubMed ID: 21854688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A utility-theoretic model for QALYs and willingness to pay.
    Klose T
    Health Econ; 2003 Jan; 12(1):17-31. PubMed ID: 12483758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The value of a QALY: individual willingness to pay for health gains under risk.
    Bobinac A; van Exel J; Rutten FF; Brouwer WB
    Pharmacoeconomics; 2014 Jan; 32(1):75-86. PubMed ID: 24293198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trying to estimate a monetary value for the QALY.
    Pinto-Prades JL; Loomes G; Brey R
    J Health Econ; 2009 May; 28(3):553-62. PubMed ID: 19327857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The distribution problem in economic evaluation: income and the valuation of costs and consequences of health care programmes.
    Donaldson C; Birch S; Gafni A
    Health Econ; 2002 Jan; 11(1):55-70. PubMed ID: 11788982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disentangling WTP per QALY data: different analytical approaches, different answers.
    Gyrd-Hansen D; Kjaer T
    Health Econ; 2012 Mar; 21(3):222-37. PubMed ID: 21254305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Willingness to pay for a quality-adjusted life year: implications for societal health care resource allocation.
    King JT; Tsevat J; Lave JR; Roberts MS
    Med Decis Making; 2005; 25(6):667-77. PubMed ID: 16282217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizability.
    Barbieri M; Drummond M; Willke R; Chancellor J; Jolain B; Towse A
    Value Health; 2005; 8(1):10-23. PubMed ID: 15841890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Willingness to pay methods in health care: a sceptical view.
    Cookson R
    Health Econ; 2003 Nov; 12(11):891-4. PubMed ID: 14601152
    [No Abstract]   [Full Text] [Related]  

  • 19. [Economic examination of the 2006/7 update of the Israeli national list of health services].
    Shmueli A; Nissan-Englcin E
    Harefuah; 2008 Jun; 147(6):488-92, 576. PubMed ID: 18693622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cost-effectiveness of influenza vaccination for people aged 50 to 64 years: an international model.
    Aballéa S; Chancellor J; Martin M; Wutzler P; Carrat F; Gasparini R; Toniolo-Neto J; Drummond M; Weinstein M
    Value Health; 2007; 10(2):98-116. PubMed ID: 17391419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.